个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Tumor-associated macrophages in lymphoma: From mechanisms to therapy

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Xiong Xingfang[1,2] * ; Xie Xiaoli[2,3] ; Wang Zhiqiang[2,3] ; Zhang Yu[1,2] ; Wang Lijuan[2,3,4,*1] ;
机构： [1]Institute of Clinical Medicine College, Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China [2]Central Laboratory, Linyi People's Hospital, Linyi 276000, Shandong Province, China. [3]Linyi Key Laboratory of Tumor Biology, Linyi 276000, Shandong Province, China. [4]Department of Hematology, Linyi People's Hospital, Linyi 276000, Shandong Province, China.
出处：
DOI： 10.1016/j.intimp.2022.109235
ISSN：

关键词： Lymphoma Tumor-associated macrophages Prognosis Targeted therapy TAM biomarker Immune checkpoints

摘要：
Lymphoma is a common hematologic malignant tumor that originates from lymph nodes or other lymphoid tissues. The tumor microenvironment (TME) plays an indispensable role in tumorigenesis, tumor development, metastasis, relapse, and drug resistance. Macrophages, which are considered as critical immune cells in the TME, influence the development of tumors. In particular, M2-like tumor-associated macrophages (TAMs) promote lymphoma growth and worsen patient prognosis. Owing to their important roles in lymphoma, TAMs hold promise as biomarkers or targets for tumor immunotherapy. In this review, we summarize the origin, recruitment, polarization, function, and mechanism of action of TAMs in lymphoma to identify potential therapeutic targets and other strategies for patients with lymphoma.Copyright © 2022 Elsevier B.V. All rights reserved.

基金：
This work was supported financially by the funding of China Natural Science to Lijuan Wang (grant number 81402353).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
第一作者：
第一作者机构： [1]Institute of Clinical Medicine College, Guangzhou University of Chinese Medicine, Guangzhou 510000, Guangdong Province, China [2]Central Laboratory, Linyi People's Hospital, Linyi 276000, Shandong Province, China.
通讯作者：
通讯机构： [2]Central Laboratory, Linyi People's Hospital, Linyi 276000, Shandong Province, China. [3]Linyi Key Laboratory of Tumor Biology, Linyi 276000, Shandong Province, China. [4]Department of Hematology, Linyi People's Hospital, Linyi 276000, Shandong Province, China. [*1]Central Laboratory, Linyi People’s Hospital, Linyi 276000, Shandong Province, China.
推荐引用方式(GB/T 7714)：
Xiong Xingfang,Xie Xiaoli,Wang Zhiqiang,et al.Tumor-associated macrophages in lymphoma: From mechanisms to therapy[J].International immunopharmacology.2022,112:109235.doi:10.1016/j.intimp.2022.109235.
APA：
Xiong Xingfang,Xie Xiaoli,Wang Zhiqiang,Zhang Yu&Wang Lijuan.(2022).Tumor-associated macrophages in lymphoma: From mechanisms to therapy.International immunopharmacology,112,
MLA：
Xiong Xingfang,et al."Tumor-associated macrophages in lymphoma: From mechanisms to therapy".International immunopharmacology 112.(2022):109235

相关文献

[1]肿瘤炎性微环境及其对肿瘤相关巨噬细胞抑制的研究进展 [2]Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness. [3]Research trends in pharmacological modulation of tumor-associated macrophages. [4]CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling [5]Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance [6]Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma [7]Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages [8]Discovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. [9]PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. [10]Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号